Written question asked by Lord Mendelsohn (Labour) on Wednesday, 15 March 2023, in the House of Lords. It was due for an answer on Wednesday, 29 March 2023. It was answered by Lord Markham (Conservative) on Tuesday, 11 April 2023 on behalf of the Department of Health and Social Care.
Coronavirus: Immunosuppression
- Question
-
To ask His Majesty's Government, further to the Written Answer by Lord Markham on 1 March (HL5824), which body will assume responsibility for ensuring that the immunocompromised will continue to be treated as a priority after the disbanding of the Antivirus and Therapeutics Taskforce, and its related programme and strategy boards.
- Answer
-
In line with the Government’s strategy of living with COVID-19, as of 31 March 2023 the Antiviral and Therapeutics Taskforce has been stood down. The treatment of COVID-19 patients will continue to be overseen by National Health Service and will operate in line with evidence-based recommendations from the National Institute for Health and Care Excellence, following the established processes in this area.
The welfare of immunocompromised patients remains a priority, hence the enhanced protections we continue to offer, including the recently announced spring booster vaccinations, free lateral flow tests and guidance in addition to COVID-19 treatments.
Secondary information
- Type
- Written question
- Reference
- HL6530
- Session
- 2022-23
- Related items
- Subjects
- Disease control Coronavirus Immunosuppression
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-06-22 17:04:24 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL6530
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL6530
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL6530